tiprankstipranks
Trending News
More News >

GE HealthCare announces NCCN Guidelines recommend use of FES PET imaging

GE HealthCare (GEHC) announced that the NCCN Clinical Practice Guidelines in Oncology for clinicians now recommend considering fluoroestradiol, FES, positron emission tomography, PET, for systemic staging in patients with recurrent or metastatic lobular breast cancer. GE HealthCare’s Cerianna injection, available in the United States, is the only FDA-approved imaging agent for the detection of estrogen receptor positive breast cancer metastases, including lobular breast cancer. The updated NCCN Guidelines expand the recommendation for the use of FES PET imaging in ER+ disease. In 2023, FES PET was included in the NCCN Guidelines for systemic staging of recurrent/stage IV ER+ breast cancer.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue